ANNALS OF THE RHEUMATIC DISEASES, vol.75, no.6, pp.1133-1138, 2016 (SCI-Expanded)
Objectives To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib.